Method for Treating Cancer with a Coxsackievirus B3 (CVB3) Variant

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a method of treating cancer, especially colorectal carcinoma, by administering a specific variant (PD variant) of Coxsackievirus B3 (CVB3). The invention utilizes a genetically modified form of the virus with unique mutations, allowing it to target and destroy cancer cells that express heparan sulfate (HS) receptors on their surface. Upon binding, the virus enters these cancer cells and causes viral lysis, effectively killing them. The PD variant is shown to be highly effective against cancer cells with HS receptors and demonstrates improved safety, with reduced undesirable side effects compared to other CVB3 strains.

Use CasesContent extracted from patent full text and abstract with AI.

• Oncolytic virotherapy for colorectal cancer, particularly cases resistant to traditional therapies like radiation or chemotherapy.
• Potential treatment for other cancers expressing heparan sulfate receptors, such as esophageal, breast, lung, pancreatic, prostate, gastric, and liver cancers.
• Combination therapy with chemotherapeutic agents or radiotherapy to enhance cancer treatment effectiveness.
• Personalized medicine by selecting patients with tumors expressing HS receptors (via diagnostic assays) for targeted therapy.
• Development of recombinant viruses with additional therapeutic genes for enhanced tumor-specific cytotoxicity.

BenefitsContent extracted from patent full text and abstract with AI.

• Selectively targets cancer cells expressing heparan sulfate, minimizing damage to normal tissues and increasing patient safety.
• Demonstrates low systemic toxicity and reduces risk of severe side effects, as shown in animal models.
• Effective in killing cancer cells, including those resistant to conventional therapies.
• Applicable to metastatic or disseminated tumors due to possible systemic immune effects and viral spread to non-injected tumor sites.
• Versatility in administration (oral, intratumoral, intravenous), increasing practicality in clinical settings.
• Ability to engineer recombinant viruses with improved genetic stability or added therapeutic payloads for enhanced efficacy.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a method for treating cancer in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a Coxsackie B3 group virus or a modified form thereof, wherein the cells of the cancer express a heparan sulfate (HS) receptor on their surface and the virus binds to said HS receptor, enters and accumulates in the cancer cells, whereby at least some cancer cells undergo viral lysis.